Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2011

View Archived Issues

New muscarinic acetylcholine M1 receptor modulators claimed

Roche discloses new modulators of metabotropic glutamate mGlu5 receptor

Novel MK2 inhibitors synthesized at Merck & Co.

SHARP trial assesses simvastatin/ezetimibe combination in chronic kidney disease

One-pot approach creates semihollow microgel capsules for simultaneous multidrug delivery

Peptide P-13 ameliorates experimental otitis media

Dehydro-alpha-lapachone is natural antiangiogenic product that targets cell adhesion

Newron Pharmaceuticals submits IND for NW-3509 in schizophrenia

Biotron begins dosing final patient in phase IIa BIT-225 trial in genotype 1 hepatitis C

Sanofi and Regeneron report phase IIb data on sarilumab

Novel PKB inhibitors presented

Eisai to market and distribute Orion's Fareston and Eldepryl in China

Treatment begins in Cerulean Pharma's phase II CRLX-101 study in NSCLC

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

GE Healthcare presents novel diagnostic imaging agents

AnaptysBio selects new antibody with potential to treat autoimmune diseases

FDA accepts sNDA for Dacogen in acute myeloid leukemia

Novadex presents new agents for HBV and HIV infections

Istituto Europeo di Oncologia patents new tubulin polymerization inhibitors

DSMB recommends discontinuation of Stallergenes' phase III trial of Actair

BioAlliance gives update on Livatag and Clonidine Lauriad

CMX-001 enters phase II trial in adenoviral disease and receives FDA fast track status

Teva completes acquisition of Taiyo Pharmaceutical

Consortium led by Ark Therapeutics receives E.U. Framework Programme 7 Grant

Watson Pharmaceuticals and Antares sign licensing agreement for Anturol gel in U.S. and Canada

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...